Vanflyta
Daiichi Sankyo Taps Innovent to Sell Vanflyta in China
Innovent Biologics, Inc. (HKEX: 01801) and Daiichi Sankyo Company (TSE: 4568) announced on August 9 that they have entered an exclusive agreement to commercialize Vanflyta (quizartinib) in China, an oral FLT3 inhibitor for a genetically defined, high-risk form of acute myeloid leukemia. Under the deal, Daiichi Sankyo keeps responsibility for developing, manufacturing, and supplying the…
